|
US5591855A
(en)
|
1994-10-14 |
1997-01-07 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
ES2301194T3
(es)
|
1997-02-05 |
2008-06-16 |
Warner-Lambert Company Llc |
Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
|
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
|
US20040006074A1
(en)
|
1998-04-28 |
2004-01-08 |
The Government Of The United States Of America |
Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
|
|
WO1999065910A1
(en)
|
1998-06-16 |
1999-12-23 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Fused azepinone cyclin dependent kinase inhibitors
|
|
NZ513487A
(en)
|
1999-01-29 |
2003-02-28 |
Univ Illinois |
The use of a P53 inhibitor for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
|
|
US6958333B1
(en)
|
1999-07-26 |
2005-10-25 |
Banyu Pharmaceutical Co., Ltd. |
Biarylurea derivatives
|
|
US6387900B1
(en)
|
1999-08-12 |
2002-05-14 |
Pharmacia & Upjohn S.P.A. |
3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
|
|
US6291504B1
(en)
|
1999-10-20 |
2001-09-18 |
Dupont Pharmaceuticals Company |
Acylsemicarbazides and their uses
|
|
WO2001044247A2
(en)
|
1999-12-16 |
2001-06-21 |
Eli Lilly And Company |
Agents and methods for the treatment of proliferative diseases
|
|
US7053070B2
(en)
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
IL152771A0
(en)
|
2000-06-26 |
2003-06-24 |
Pfizer Prod Inc |
PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
|
|
TR200401316T4
(tr)
|
2000-09-29 |
2004-07-21 |
Eli Lilly And Company |
Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
|
|
WO2002044174A2
(en)
|
2000-12-01 |
2002-06-06 |
Bristol-Myers Squibb Pharma Company |
3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors
|
|
WO2002069892A2
(en)
|
2001-02-28 |
2002-09-12 |
Temple University Of The Commonwealth System Of Higher Education |
METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
|
|
EP1392361A4
(en)
*
|
2001-05-11 |
2009-08-05 |
Univ Texas |
ANTI-CD26 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CD26 EXPRESSIVE CELLS
|
|
ES2251677T3
(es)
|
2002-01-22 |
2006-05-01 |
Warner-Lambert Company Llc |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
|
|
WO2003093469A2
(en)
|
2002-05-01 |
2003-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
|
EP1590341B1
(en)
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
PT1636236E
(pt)
|
2003-05-22 |
2013-12-16 |
Nerviano Medical Sciences Srl |
Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase
|
|
ATE412650T1
(de)
|
2003-07-11 |
2008-11-15 |
Warner Lambert Co |
Isethionat salz eines selektiven cdk4 inhibitors
|
|
KR100798161B1
(ko)
|
2003-10-23 |
2008-01-28 |
에프. 호프만-라 로슈 아게 |
신경병적 또는 신경정신병적 장애의 치료에서 ｇｌｙｔ-1저해제로서 사용하기 위한 트라이아자-스피로피페리딘유도체
|
|
GB0327380D0
(en)
|
2003-11-25 |
2003-12-31 |
Cyclacel Ltd |
Method
|
|
CA2561516A1
(en)
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
WO2005100999A2
(en)
|
2004-04-08 |
2005-10-27 |
Cornell Research Foundation, Inc. |
Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
|
|
ITMI20040874A1
(it)
|
2004-04-30 |
2004-07-30 |
Ist Naz Stud Cura Dei Tumori |
Derivati indolici ed azaindolici con azione antitumorale
|
|
EP1846408B1
(en)
|
2005-01-14 |
2013-03-20 |
Janssen Pharmaceutica NV |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
|
KR20070107707A
(ko)
|
2005-01-21 |
2007-11-07 |
아스텍스 테라퓨틱스 리미티드 |
피라졸 키나제 억제제와 추가 항종양제의 조합물
|
|
WO2006127587A1
(en)
|
2005-05-20 |
2006-11-30 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyridines useful as inhibitors of protein kinase
|
|
WO2007025090A2
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
|
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
|
JP2009518351A
(ja)
|
2005-12-09 |
2009-05-07 |
エフ．ホフマン−ラ ロシュ アーゲー |
肥満症の処置に有用な三環性アミド誘導体
|
|
WO2007075783A2
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
|
|
CA2645633A1
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
US20070270362A1
(en)
|
2006-05-18 |
2007-11-22 |
The University Of Washington |
Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
|
|
EP2043651A2
(en)
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
CA2672898A1
(en)
|
2006-12-14 |
2008-06-26 |
Panacea Pharmaceuticals, Inc. |
Methods of neuroprotection by cyclin-dependent kinase inhibition
|
|
CA2672518A1
(en)
|
2006-12-22 |
2008-07-03 |
Novartis Ag |
Organic compounds and their uses
|
|
JP2010531364A
(ja)
|
2007-06-25 |
2010-09-24 |
ニューロジェン・コーポレーション |
ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体
|
|
US9259399B2
(en)
|
2007-11-07 |
2016-02-16 |
Cornell University |
Targeting CDK4 and CDK6 in cancer therapy
|
|
BRPI0821209A2
(pt)
|
2007-12-19 |
2019-09-24 |
Amgen Inc |
composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
|
|
EP2320903B1
(en)
|
2008-07-29 |
2017-01-18 |
Nerviano Medical Sciences S.r.l. |
THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
|
|
ES2522346T3
(es)
*
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
CN102231983A
(zh)
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
|
|
JP2012504646A
(ja)
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
|
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
|
EP3406260B1
(en)
|
2009-05-13 |
2020-09-23 |
The University of North Carolina at Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
WO2011103485A1
(en)
|
2010-02-18 |
2011-08-25 |
Medivation Technologies, Inc. |
Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
KR102051881B1
(ko)
*
|
2010-10-25 |
2019-12-04 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
|
CN103180324A
(zh)
|
2010-11-02 |
2013-06-26 |
普罗美加公司 |
腔肠素衍生物及其使用方法
|
|
EP2640394A4
(en)
|
2010-11-17 |
2015-02-25 |
Univ North Carolina |
PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
|
|
DK2655375T3
(en)
|
2010-12-23 |
2015-03-09 |
Sanofi Sa |
PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
|
|
CN103703000B
(zh)
*
|
2011-03-23 |
2015-11-25 |
安姆根有限公司 |
Cdk4/6和flt3的稠合三环双重抑制剂
|
|
CN103635189B
(zh)
|
2011-07-01 |
2016-05-04 |
诺华股份有限公司 |
用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
|
|
AU2013239816B2
(en)
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
EP2841417A1
(en)
|
2012-04-26 |
2015-03-04 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
US9241941B2
(en)
|
2012-09-20 |
2016-01-26 |
Memorial Sloan-Kettering Cancer Center |
Methods for treatment of lymphomas with mutations in cell cycle genes
|
|
WO2014144596A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
HK1222766A1
(zh)
|
2013-03-15 |
2017-07-14 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
|
DK2968290T3
(da)
|
2013-03-15 |
2019-11-25 |
G1 Therapeutics Inc |
Transient beskyttelse af normale celler under kemoterapi
|
|
HK1215374A1
(zh)
|
2013-04-08 |
2016-08-26 |
Pharmacyclics Llc |
依鲁替尼联合疗法
|
|
US20160257688A1
(en)
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
|
WO2015084892A1
(en)
|
2013-12-02 |
2015-06-11 |
Cornell University |
Methods for treating b cell proliferative disorders
|
|
WO2015161285A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016126889A1
(en)
|
2015-02-03 |
2016-08-11 |
G1 Therapeutics, Inc. |
Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
|